213 related articles for article (PubMed ID: 34623599)
1. Leptomeningeal disease in glioblastoma: endgame or opportunity?
Akmal S; Ginalis EE; Patel NV; Aiken R; Dicpinigaitis AJ; Hanft SJ
J Neurooncol; 2021 Nov; 155(2):107-115. PubMed ID: 34623599
[TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution.
Mandel JJ; Yust-Katz S; Cachia D; Wu J; Liu D; de Groot JF; Yung AW; Gilbert MR
J Neurooncol; 2014 Dec; 120(3):597-605. PubMed ID: 25168214
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
Singh E; Gurses ME; Costello MC; Berke C; Lu VM; Daggubati L; Komotar RJ; Ivan ME; Shah AH
J Neurooncol; 2024 Mar; 167(1):39-47. PubMed ID: 38294637
[TBL] [Abstract][Full Text] [Related]
4. Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience.
Andersen BM; Miranda C; Hatzoglou V; DeAngelis LM; Miller AM
Neurology; 2019 May; 92(21):e2483-e2491. PubMed ID: 31019097
[TBL] [Abstract][Full Text] [Related]
5. Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis.
Roldán G; Scott J; George D; Parney I; Easaw J; Cairncross G; Forsyth P; Yan E
Can J Neurol Sci; 2008 May; 35(2):204-9. PubMed ID: 18574935
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Therapeutic Updates in Leptomeningeal Disease.
Roy-O'Reilly MA; Lanman T; Ruiz A; Rogawski D; Stocksdale B; Nagpal S
Curr Oncol Rep; 2023 Aug; 25(8):937-950. PubMed ID: 37256537
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy for leptomeningeal disease in breast cancer.
Bartsch R; Jerzak KJ; Larrouquere L; Müller V; Le Rhun E
Cancer Treat Rev; 2024 Jan; 122():102653. PubMed ID: 38118373
[TBL] [Abstract][Full Text] [Related]
8. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.
Piña Y; Yadugiri S; Yeboa DN; Ferguson SD; Forsyth PA; Oliva ICG
Curr Oncol Rep; 2022 Jan; 24(1):43-54. PubMed ID: 35059999
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J; Gellrich FF; Engellandt K; Meinhardt M; Westphal D; Beissert S; Meier F; Glitza Oliva IC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511202
[TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
11. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials.
Palmisciano P; Watanabe G; Conching A; Ogasawara C; Vojnic M; D'Amico RS
J Neurooncol; 2022 Oct; 160(1):79-100. PubMed ID: 35999434
[TBL] [Abstract][Full Text] [Related]
13. Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity.
O'Connor CA; Park JS; Kaley T; Kezlarian B; Edelweiss M; Yang TJ; Park W; Reidy D; Varghese AM; Yu KH; O'Reilly EM
Pancreatology; 2021 Apr; 21(3):599-605. PubMed ID: 33582005
[TBL] [Abstract][Full Text] [Related]
14. A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers.
Jafari F; Nodeh MM; Hosseinjani H; Baharara H; Azad S; Arasteh O; Johnston TP; Sahebkar A
Curr Med Chem; 2024; 31(19):2732-2750. PubMed ID: 37157199
[TBL] [Abstract][Full Text] [Related]
15. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.
Nguyen A; Nguyen A; Dada OT; Desai PD; Ricci JC; Godbole NB; Pierre K; Lucke-Wold B
Curr Oncol; 2023 Jun; 30(6):5906-5931. PubMed ID: 37366925
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials.
Buszek SM; Chung C
Front Oncol; 2019; 9():1224. PubMed ID: 31803614
[No Abstract] [Full Text] [Related]
17. Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.
Thomas KH; Ramirez RA
Ochsner J; 2017; 17(4):362-378. PubMed ID: 29230121
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal methotrexate in combination with systemic chemotherapy in glioblastoma patients with leptomeningeal dissemination: A retrospective analysis.
Kang X; Chen F; Yang SB; Wang YL; Qian ZH; Li Y; Lin H; Li P; Peng YC; Wang XM; Li WB
World J Clin Cases; 2022 Jun; 10(17):5595-5605. PubMed ID: 35979103
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
20. Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination.
You HJ; Park HY; Kim J; Lee IH; Seol HJ; Lee JI; Kim ST; Kong DS; Nam DH
Medicine (Baltimore); 2016 Jul; 95(27):e4109. PubMed ID: 27399113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
